Skip to main content
SpringerLink
Log in

Des mutations de KRAS aux mutations de RAS : vers une meilleure définition de la réponse aux anticorps anti-EGFR dans le cancer colorectal métastatique

From KRAS mutations to RAS mutations: Towards a better definition of response to anti-EGFR antibodies in metastatic colorectal cancer

  • Mise au Point / Update
  • Published:
Oncologie

Résumé

L’identification des mutations de KRAS comme facteur prédictif de résistance aux anticorps anti-EGFR a permis de faire un grand pas dans la personnalisation du traitement du cancer colorectal métastatique. Récemment, la recherche d’autres mutations au niveau des gènes de la famille RAS a fait la preuve de son intérêt dans l’identification des patients pouvant tirer bénéfice de ces anticorps anti-EGFR. Parallèlement, des travaux plus fondamentaux ont permis de mieux comprendre les mécanismes de résistance secondaire aux anticorps anti-EGFR et d’envisager, à court ou moyen terme, la recherche des mutations de KRAS ou de RAS au niveau du sang périphérique.

Abstract

The identification of KRAS mutations as a predictive marker of resistance to anti-EGFR antibodies has been considered as a major step in the personalized treatment of metastatic colorectal cancer. Recently, other mutations in genes of the RAS family have demonstrated their role in identifying patients who may benefit from anti-EGFR. Meanwhile, more fundamental works have led to better understand the mechanisms of secondary resistance to anti-EGFR antibodies and also to consider the possibility to a rapid research of KRAS or RAS mutations in peripheral blood.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Agence nationale de sécurité des médicaments et des produits de santé (2014) Erbitux® (cetuximab): importance de la détermination du statut mutationnel des gènes RAS de type sauvage (exons 2, 3 et 4 des gènes KRAS et NRAS) avant d’instaurer un traitement par Erbitux® — Lettre aux professionnels de santé — 06/01/2014 http://ansm.sante.fr/ (accès le 19/01/2014)

    Google Scholar 

  2. Amado RG, Wolf M, Peeters M, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626–1634

    Article  PubMed  CAS  Google Scholar 

  3. Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28: 1254–1261

    Article  PubMed  CAS  Google Scholar 

  4. Bokemeyer C, Bondarenko I, Hartmann JT, et al. (2011) Efficacy according to biomarker status of cetuximab plus Folfox4 as firstline treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535–1546

    Article  PubMed  CAS  Google Scholar 

  5. Bokemeyer C, Bondarenko I, Makhson A, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663–671

    Article  PubMed  CAS  Google Scholar 

  6. COSMIC (Catalogue of Somatic Mutations in Cancer) (2014) http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ (accès le 19/01/2014)

  7. Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351: 337–345

    Article  PubMed  CAS  Google Scholar 

  8. De Roock W, Claes B, Bernasconi D, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753–762

    Article  PubMed  CAS  Google Scholar 

  9. De Roock W, Piessevaux H, De Schutter J, et al. (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508–515

    Article  PubMed  Google Scholar 

  10. Di Fiore F, Blanchard F, Charbonnier F, et al. (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 1166–1169

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Diaz LA Jr, Williams RT, Wu J, et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537–540

    PubMed Central  PubMed  Google Scholar 

  12. Douillard JY, Oliner KS, Siena S, et al. (2013) Panitumumab-Folfox4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023–1034

    Article  PubMed  CAS  Google Scholar 

  13. Douillard JY, Siena S, Cassidy J, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (Folfox4) versus Folfox4 alone as firstline treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697–4705

    Article  PubMed  CAS  Google Scholar 

  14. Esposito C, Rachiglio AM, La Porta ML, et al. (2013) The S492R EGFR ectodomain mutation is never detected in KRAS wild type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biology & Therapy 14: [Epub ahead of print]

  15. Heinemann V, Fischer von Weikersthal L, Decker T, et al. (2013) Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of Folfiri plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. European Cancer Congress Abstract LBA17

    Google Scholar 

  16. Heinemann V, Fischer von Weikersthal L, Decker T, et al. (2013) Randomized comparison of Folfiri plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol 31 (suppl; abstr LBA3506)

  17. Institut national du cancer. Les plateformes de génétique moléculaire en France. http://www.e-cancer.fr (accès le 19/01/2014)

  18. Jacobs B, De Roock W, Piessevaux H, et al. (2009) Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27: 5068–5074

    Article  PubMed  CAS  Google Scholar 

  19. Jiang Z, Li C, Li F, Wang X (2013) EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PLoS One 8: e56205

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  20. Jonker D, Karapetis C, Moore M, et al. (2007) Randomized Phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). American Association for Cancer Research Annual Meeting late breaking abstract 1

    Google Scholar 

  21. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040–2048

    Article  PubMed  CAS  Google Scholar 

  22. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. (2008) KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757–1765

    Article  PubMed  CAS  Google Scholar 

  23. Khambata-Ford S, Garrett CR, Meropol NJ, et al. (2007) Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230–3237

    Article  PubMed  CAS  Google Scholar 

  24. Laurent-Puig P, Cayre A, Manceau G, et al. (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924–5930

    Article  PubMed  CAS  Google Scholar 

  25. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24: 4914–4921

    Article  PubMed  CAS  Google Scholar 

  26. Lievre A, Bachet JB, Boige V, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374–379

    Article  PubMed  CAS  Google Scholar 

  27. Lievre A, Bachet JB, Le Corre D, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992–3995

    Article  PubMed  CAS  Google Scholar 

  28. Loupakis F, Ruzzo A, Cremolini C, et al. (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101: 715–721

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  29. Metges J, Raoul J, Achour N, et al. (2010) PANERB study: panitumumab after cetuximab-based regimen failure. J Clin Oncol 28 (suppl; abstr e14000)

  30. Misale S, Yaeger R, Hobor S, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532–536

    PubMed Central  PubMed  CAS  Google Scholar 

  31. Modest D, Fischer von Weikersthal L, Stintzing S, et al. (2013) Folfiri plus cetuximab versus Folfiri plus bevacizumab as firstline treatment of KRAS-wild type metastatic colorectal cancer: german AIO study KRK-0306 (FIRE-3). Ann Oncol 24: iv22–iv23: O-0029

    Article  Google Scholar 

  32. Montagut C, Dalmases A, Bellosillo B, et al. (2012) Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18: 221–223

    Article  PubMed  CAS  Google Scholar 

  33. Moroni M, Veronese S, Benvenuti S, et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279–286

    Article  PubMed  CAS  Google Scholar 

  34. Peeters M, Price TJ, Cervantes A, et al. (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (Folfiri) compared with Folfiri alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706–4713

    Article  PubMed  CAS  Google Scholar 

  35. Rivera F, Karthaus M, Fasola G, et al. (2013) KRAS/NRAS mutations in PEAK: a randomized phase 2 study of 1st line treatment with Folfox6 + panitumumab or bevacizumab for wild-type KRAS MCRC Ann Oncol 24: iv16: O-0013

    Google Scholar 

  36. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208

    Article  PubMed  CAS  Google Scholar 

  37. Sartore-Bianchi A, Moroni M, Veronese S, et al. (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25: 3238–3245

    Article  PubMed  CAS  Google Scholar 

  38. Thierry AR, Mouliere F, El Messaoudi S, et al. (2012) Circulating DNA analysis and concordance with tumor section analysis in the detection of KRAS and BRAF point mutations from metastatic colorectal cancer. J Clin Oncol 30: (suppl; abstr 10505)

  39. Van Cutsem E, Kohne CH, Hitre E, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408–1417

    Article  PubMed  Google Scholar 

  40. Van Cutsem E, Kohne CH, Lang I, et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011–2019

    Article  PubMed  CAS  Google Scholar 

  41. Van Cutsem E, Peeters M, Siena S, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664

    Article  PubMed  CAS  Google Scholar 

  42. Vaughn CP, Zobell SD, Furtado LV, et al. (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50: 307–312

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département d’oncologie médicale, institut Curie, Ensemble hospitalier, 35, rue Dailly, F-92210, Saint-Cloud, France

    A. Lièvre

  2. UFR des sciences de la santé, université Versailles-Saint-Quentin, 2, avenue de la source de la Bièvre, F-78180, Montigny-Le-Bretonneux, France

    A. Lièvre

Authors
  1. A. Lièvre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Lièvre.

About this article

Cite this article

Lièvre, A. Des mutations de KRAS aux mutations de RAS : vers une meilleure définition de la réponse aux anticorps anti-EGFR dans le cancer colorectal métastatique. Oncologie 16, 120–128 (2014). https://doi.org/10.1007/s10269-014-2376-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-014-2376-4

Mots clés

Keywords

Search

Navigation